Tumeur urothéliale de vessie chez le patient « fragile »

25 mars 2010

Auteurs : P. Mongiat-Artus, C. Pfister, C. Théodore, R. De Crevoisier, J. Guillotreau
Référence : Prog Urol, 2010, 20, S54, suppl. S1




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., Skinner E., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 2001 ;  19 : 666-675 [cross-ref]
Mills R.D., Turner W.H., Fleischmann A., Markwalder R., Thalmann G.N., Studer U.E. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy J Urol 2001 ;  166 : 19-23 [cross-ref]
Stein J.P., Skinner D.G. The role of lymphadenectomy in high-grade invasive bladder cancer Urol Clin North Am 2005 ;  32 : 187-197 [inter-ref]
Quek M.L., Flanigan R.C. The role of lymph node density in bladder cancer prognostication World J Urol 2009 ;  27 : 27 [inter-ref]
Wiesner C., Salzer A., Thomas C., Gellermann-Schultes C., Gillitzer R., Hampel C., et al. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer : prediction by lymph node positivity and density BJU Int 2009 ;  104 : 331-335 [cross-ref]
Dotan Z.A., Kavanagh K., Yossepowitch O., Kaag M., Olgac S., Donat M., et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival J Urol 2007 ;  178 : 2308-2312discussion 2313.
 [cross-ref]
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer : a systematic review and meta-analysis of individual patient data Eur Urol 2005 ;  48 : 189
Stadler W.M., Lerner S.P., Groshen S., Stein J.P., Skinner D.G., Raghavan D., et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer J Clin Oncol 2009 ;  27 : 239s(abstr 5017).
Dash A., Pettus J.A., Herr H.W., Bochner B.H., Dalbagni G., Donat S.M., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 2008 ;  113 : 2471-2477 [cross-ref]
Dorff T.B., Tsao-Wei D., Miranda G., Skinner D.G., Stein J.P., Quinn D.I. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience W World J Urol 2009 ;  27 : 39-44 [cross-ref]
Lebret T., Mejean A. Metastases from urethelial carcinoma: role of chemotherapy Prog Urol 2008 ;  18 : S261-S276
Cognetti F., Ruggeri E.M., Felici A., Gallucci M., Muto G., Pollera C.F., et al. Adjuvant chemotherapy (AC) with cisplatin+gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial J Clin Oncol 2008 ;  26 : abstr 5023.
De Santis M., Bellmunt Molins J., de Wit R., Mead B., Kerst J.M., Leahy M., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): updated phase II results and risk group analysis of EORTC study 30986 J Clin Oncol 2008 ;  26 : abstr 5031.
Calabro F., Lorusso V., Rosati G., Manzione L., Frassineti L., Sava T. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma Cancer 2009 ;  115 : 2652-2659 [cross-ref]
Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 2001 ;  92 : 2993-2998 [cross-ref]
Bajorin D.F., Dodd P.M., Mazumdar M.V., Fazzari M., McCaffrey J.A., Scher H.I. Long-term survival in metastatic transitionalcell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 1999 ;  17 : 3173-3181 [cross-ref]
Pollack A., Zagars G.K., Dinney C.P., Swanson D.A., von Eschenbach A.C. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients Cancer 1994 ;  74 : 2819-2827 [cross-ref]
Mak R.H., Zietman A.L., Heney N.M., Kaufman D.S., Shipley W.U. Bladder preservation: optimizing radiotherapy and integrated treatment strategies BJU Int 2008 ;  102 : 1345-1353 [cross-ref]
Irani J., Bernardini S., Bonnal J.L., Chauvet B., Colombel M., Davin J.L., et al. Urothelial tumors Prog Urol 2007 ;  17 : 1065-1098 [cross-ref]






© 2010 
Elsevier Masson SAS. Tous droits réservés.